Probiotics as a Treatment for "Metabolic Depression"? A Rationale for Future Studies

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 14; no. 4; p. 384
• Main Authors: Gawlik-Kotelnicka, Oliwia, Strzelecki, Dominik
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20.04.2021; MDPI
• Subjects: Anxiety; Behavior; Comorbidity; depression; Diabetes; Inflammation; Insulin; Intervention; Lifestyles; Liver diseases; Mental depression; Metabolic disorders; Metabolic syndrome; Metabolites; Microbiota; Mortality; Obesity; Prebiotics; Probiotics; Review; Stress; metabolic syndrome; microbiota; depression; obesity; probiotics
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph14040384

Depression and metabolic diseases often coexist, having several features in common, e.g., chronic low-grade inflammation and intestinal dysbiosis. Different microbiota interventions have been proposed to be used as a treatment for these disorders. In the paper, we review the efficacy of probiotics in depressive disorders, obesity, metabolic syndrome and its liver equivalent based on the published experimental studies, clinical trials and meta-analyses. Probiotics seem to be effective in reducing depressive symptoms when administered in addition to antidepressants. Additionally, probiotics intake may ameliorate some of the clinical components of metabolic diseases. However, standardized methodology regarding probiotics use in clinical trials has not been established yet. In this narrative review, we discuss current knowledge on the recently used methodology with its strengths and limitations and propose criteria that may be implemented to create a new study of the effectiveness of probiotics in depressive disorders comorbid with metabolic abnormalities. We put across our choice on type of study population, probiotics genus, strains, dosages and formulations, intervention period, as well as primary and secondary outcome measures.